Molecularly Matched Therapy and Outcomes in End-Stage Cancers

Lead Acredit professors Anne Hansen Ree and Kjersti Flatmark have published a paper outlining the final results from the MetAction study. In their paper, the professors note that the current limitations in the use of precision cancer medicine might lie in bridging the gap between what we know about cancer gene mutations and what we can do with clinical interventions. Dr Ree noted that where there are multiple mutations in the tumor that has spread to other sites in the body, the main challenge is in prioritising the driver genes, accounting for markers of resistance and procurement of sufficient information to maintain safe treatments for patients.

“We performed a systematic interpretation of identified tumor gene mutations with respect to sensitivity and resistance, as well as patient tolerability to single-agent or combinational matched therapies in patients with end-stage cancer. Half the tested patients were found eligible for molecularly matched therapies, of whom 30% had partial or complete response with negligible side effects.”, stated Dr Ree.

Unfortunately, precision cancer medicine is not yet part of the standard treatment in the Norwegian public health service. Dr Ree says, “Our MetAction study, funded by the Research Council of Norway (2014-2017), concluded in December 2019, represents the first Norwegian initiative in precision cancer medicine.”

Read Anne and Kjersti’s MetAction paper here.